https://doi.org/10.1093/jpids/piad006
Journal of the Pediatric Infectious Diseases Society; Teoh Z, Willis ZI
Mar 18th, 2023 - Two new articles describe the use and implementation of monoclonal antibodies to treat COVID-19 in children. While these studies provide valuable guidance for pediatric clinicians, more studies of monoclonal antibodies and other COVID-19 therapies in children are needed.
https://doi.org/10.1111/tid.14055
Transplant Infectious Disease : an Official Journal of Th... Tayyar R, Wong LK et. al.
Mar 18th, 2023 - Transplant and hematologic malignancy patients have high Coronavirus disease 2019 (COVID-19) mortality and impaired vaccination responses. Omicron variant evades several monoclonal antibodies previously used in immunocompromised patients. Polyclonal COVID-19 convalescent plasma (CCP) may provide broader neutralizing capacity against new variants at high titers. Vaccination increases severe acut...
https://doi.org/10.1111/liv.15557
Liver International : Official Journal of the Internation... Montalbano M, Piccolo P et. al.
Mar 18th, 2023 - Weaker responses have been described after two doses of anti-SARS-CoV2 vaccination in liver transplant recipients. At the Italian National Institute for Infectious Diseases, 122 liver transplant recipients (84% males, median age 64 years) were tested for humoral and cell-mediated immune response after a third doses of anti-SARS-CoV2 mRNA vaccines. Humoral response was measured by quantifying an...
https://doi.org/10.1097/MCP.0000000000000954
Current Opinion in Pulmonary Medicine; Terry PD, Heidel RE et. al.
Mar 18th, 2023 - Three years after the emergence of coronavirus disease 2019 (COVID-19), many studies have examined the association between asthma and COVID-related morbidity and mortality, with most showing that asthma does not increase risk. However, the U.S. Centers for Disease Control (CDC) currently suggests that patients with severe asthma may, nonetheless, be particularly vulnerable to COVID-19-related m...
https://doi.org/10.1093/jpids/piac124
Journal of the Pediatric Infectious Diseases Society; Sherman G, Lamb GS et. al.
Mar 18th, 2023 - Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died.
https://doi.org/10.1111/cts.13511
Clinical and Translational Science; Bauer RN, Teterina A et. al.
Mar 18th, 2023 - Observational studies have identified potential prognostic value for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) viral load and anti-SARS-CoV-2 antibodies in COVID-19. However, viral load in nasopharyngeal swabs produced inconsistent results in prognostic analyses, and the prognostic value of viral load or antibodies has not been confirmed in large clinical trials. COVACTA and ...
https://doi.org/10.1371/journal.pone.0283197
PloS One; Alnour TMS, Al-Amer O et. al.
Mar 18th, 2023 - The increase in severe acute respiratory syndrome SARS-CoV-2 has invariably affected medical professionals in their training, academic and professional development. The present study was an interventional descriptive study aimed at reducing the risk of exposure to COVID-19 and enabling physical attendance to the practical session for applied medical students by establishing and implementing a s...
https://doi.org/10.1080/22221751.2023.2192817
Emerging Microbes & Infections; Liu Z, Lu L et. al.
Mar 18th, 2023 - First-generation SARS-CoV-2 vaccines based on different platforms have significantly reduced hospitalization and death. However, the constant evolution of SARS-CoV-2 has only prolonged the global pandemic. Recent emergence of the Omicron subvariants XBB and BQ.1.1 has posed an unprecedented challenge to the efficacy of current broad-spectrum SARS-CoV-2 vaccines. Several lines of evidence have d...
https://doi.org/10.1186/s13018-023-03651-6
Journal of Orthopaedic Surgery and Research; Migliorini F, Bell A et. al.
Mar 17th, 2023 - Immune-mediated conditions associated to Corona Virus Disease-19 (COVID-19) have been reported, including vasculitis, antiphospholipid antibody syndrome, myositis, and lupus. Emerging studies have reported the potential occurrence of reactive arthritis in patients previously infected with COVID-19. This systematic review summarised the current evidence on the occurrence of reactive arthritis in...
https://doi.org/10.1002/rmv.2439
Reviews in Medical Virology; Miljanovic D, Cirkovic A et. al.
Mar 17th, 2023 - Until now, the treatment protocols for COVID-19 have been revised multiple times. The use and approval of therapeutic monoclonal antibodies (mAbs) for COVID-19 treatment represent exceptional achievements in modern science, technology and medicine. SARS-CoV-2 Omicron evasion of pre-existing immunity represents a serious public health problem nowadays. This systematic review with meta-analysis p...
https://doi.org/10.1038/s41467-023-37128-1
Nature Communications; Takano T, Sato T et. al.
Mar 17th, 2023 - The immunogenicity of mRNA vaccines has not been well studied when compared to different vaccine modalities in the context of additional boosters. Here we show that longitudinal analysis reveals more sustained SARS-CoV-2 spike receptor-binding domain (RBD)-binding IgG titers with the breadth to antigenically distinct variants by the S-268019-b spike protein booster compared to the BNT162b2 mRNA...
https://doi.org/10.1016/j.vaccine.2023.02.083
Vaccine Estephan L, Liu LT et. al.
Mar 17th, 2023 - The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) Working Group has prepared standardized templates to describe the key considerations for the benefit-risk assessment of several vaccine platform technologies, including protein subunit vaccines. This article uses the BRAVATO template to review the features of the MVC-COV1901 vaccine, a recombinant protein sub...
https://doi.org/10.1080/14760584.2023.2191716
Expert Review of Vaccines; Tan TT, Ng HJ et. al.
Mar 16th, 2023 - Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including administration of booster doses, continues to be the most effective method for controlling COVID-19-related complications including progression to severe illness and death.However, there is mounting evidence that more needs to be done to protect individuals with compromised immune function. Here, we revi...
https://doi.org/10.17219/acem/161461
Advances in Clinical and Experimental Medicine : Official... Stępień M, Świątoniowska-Lonc N et. al.
Mar 16th, 2023 - Since the beginning of the coronavirus disease (COVID-19) pandemic, numerous infections have been observed with various symptoms and degrees of severity. Not all patients have had a confirmation of infection made using reverse transcription polymerase chain reaction (RT-PCR) or antigen tests. It has been observed that some people, including convalescents or those without knowledge of a past inf...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014096
The Journal of Clinical Investigation; Casadevall A, Focosi D
Mar 16th, 2023 - COVID-19 in immunocompromised hosts has emerged as a difficult therapeutic management problem. Immunocompromised hosts mount weak responses to SARS-CoV-2 and manifest infection outcomes ranging from severe disease to persistent infection. Weakened immune systems mean greater viral loads and increased opportunities for viral evolution. Gupta, Konnova, et al. report the emergence of resistant SAR...
https://doi.org/10.1371/journal.pone.0281915
PloS One; Goodwin AT, Thompson JS et. al.
Mar 16th, 2023 - Antivirals, such as molnupiravir, and SARS-CoV-2 neutralising monoclonal antibodies (nMAbs), such as sotrovimab, reduced the risk of hospitalisation and death in clinical trials of high-risk non-hospitalised patients with Covid-19. However, the real-world benefits of these drugs are unclear. To evaluate the characteristics and outcomes of high-risk patients referred for outpatient antiviral or ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013288
Nature Communications; Calvaresi V, Wrobel AG et. al.
Mar 16th, 2023 - SARS-CoV-2 spike glycoprotein mediates receptor binding and subsequent membrane fusion. It exists in a range of conformations, including a closed state unable to bind the ACE2 receptor, and an open state that does so but displays more exposed antigenic surface. Spikes of variants of concern (VOCs) acquired amino acid changes linked to increased virulence and immune evasion. Here, using HDX-MS, ...
https://www.medpagetoday.com/infectiousdisease/covid19/103546
Mar 15th, 2023 - Nirmatrelvir-ritonavir (Paxlovid) wards off severe disease in high-risk COVID patients, but drug interactions at the individual level often disfavor its use, said FDA staff in briefing documents released ahead of an advisory committee meeting. On Thursday, the Antimicrobial Drugs Advisory Committee will weigh in on the strength of evidence for use of the oral antiviral in outpatients at risk fo...
https://doi.org/10.1073/pnas.2220320120
Proceedings of the National Academy of Sciences of the Un... Humbert M, Olofsson A et. al.
Mar 15th, 2023 - Pre-existing SARS-CoV-2-reactive T cells have been identified in SARS-CoV-2-unexposed individuals, potentially modulating COVID-19 and vaccination outcomes. Here, we provide evidence that functional cross-reactive memory CD4+ T cell immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is established in early childhood, mirroring early seroconversion with seasonal human ...
https://doi.org/10.1080/14767058.2023.2183750
The Journal of Maternal-fetal & Neonatal Medicine : the O... Askary E, Moradi Alamdarloo S et. al.
Mar 13th, 2023 - Even through the fact that pregnant women are more and more severely infected with COVID-19 disease, there are still doubts about vaccinating these people due to the lack of sufficient evidence base information. So in this systematic review, we decided to study vaccinated and unvaccinated pregnant women regarding maternal, fetal and neonatal complications and outcomes. Between 30 December 2019 ...
